Am I Suing My Doctor? No — a GLP-1 Claim Is Against the Manufacturer

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Suing the Maker Is Not Suing Your Doctor

The claim is against the manufacturer — your doctor isn't the target. See if your situation fits the current criteria.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

No. A GLP-1 injury claim is brought against the drug manufacturer that made and labeled the medication — Novo Nordisk or Eli Lilly — not against your prescribing doctor, your pharmacist, or your clinic. Your physician is not a defendant, is not accused of malpractice, and is not named in the complaint. The prescriber is far more often the source of the records that support a claim than a target of it.

The fear almost nobody says out loud

People rarely ask this directly. They ask whether a claim will “cause trouble,” or whether their doctor will find out. Underneath is usually a simple worry: I like my doctor. She was trying to help me. I don’t want to do this to her.

That deserves a direct answer rather than a footnote. These lawsuits do not involve your doctor as a defendant. Nothing you tell us becomes an accusation against her. The claim is aimed at a corporation, and the corporation wrote the warnings.

Two different kinds of case, and this is not the other one

Medical malpractice claims say a specific clinician fell below the standard of care — misread a test, chose the wrong treatment, missed something a careful physician would have caught. That is a case about a person’s judgment, and it is not what this is.

A product-liability claim says something different: that the company that designed, tested, marketed and labeled a medication did not adequately warn patients and physicians about a risk it knew or should have known about. The question is what was on the label and in the company’s files, not what happened in your exam room. A doctor prescribes based on what the manufacturer provides; if that was incomplete, the doctor worked from the same incomplete picture the patient did — which makes this, in a real sense, a claim on your doctor’s behalf as much as your own.

Who the defendants actually are

• Novo Nordisk — Ozempic, Wegovy, and Rybelsus (semaglutide).
• Eli Lilly — Mounjaro, Zepbound, and Trulicity.

The federal cases are consolidated before Judge Karen S. Marston in the Eastern District of Pennsylvania: MDL 3094 for gastrointestinal injuries and MDL 3163 for NAION vision loss. In none of these proceedings are individual prescribing physicians defendants.

Your doctor is usually the most helpful person in the file

Claims in both tracks are built almost entirely out of medical records: the gastroenterologist who ordered a gastric emptying study, the hospital that admitted you, the ophthalmologist who diagnosed NAION.

Requesting them is a routine administrative act — the same request anyone makes when changing practices. It is not a subpoena, not a complaint, and it does not put your physician on notice of anything adverse. Patients here frequently report that their own doctor was the first to say the medication might be responsible. That physician is the strongest corroborating voice you have.

What a claim asks of you, and what it does not

• It does not ask you to stop seeing your doctor, change practices, or switch pharmacies.
• It does not ask you to accuse anyone of malpractice or to complain to a medical board.
• It does not ask you to stop or continue a prescription. That is a medical decision between you and your prescriber, and not ours to advise on.
• It does ask you for records — prescriber and pharmacy names and addresses, start and stop dates by month and year, diagnosis dates, and the hospital or ER where you were treated.
• It does ask you to keep what you still have — pens, boxes, packaging, receipts, letters and emails. Pharmacy records are how brand-name use gets proven, and brand matters to eligibility in both tracks.

An honest note on where the litigation stands

No GLP-1 case has been tried and none has settled. The stomach-injury proceeding has a Rule 702 hearing on expert evidence underway September 14 through 18, 2026, and in August 2025 the court there ruled that gastroparesis claims must rest on a properly performed gastric emptying study rather than symptoms alone. The vision-loss proceeding, created December 2025, has issued no merits rulings. European regulators concluded in June 2025 that NAION is a very rare side effect of semaglutide medicines; the manufacturers dispute causation in both tracks.

Common questions

Common questions: can you sue?, still taking Ozempic?, is it too late to file?, still on a GLP-1, stopped taking it, switched drugs, calling for a parent, and how compensation works.